DelveInsight’s “ESCLC Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the ESCLC pipeline landscape. It covers the ESCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ESCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the ESCLC Pipeline @ https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight

Key Takeaways from the ESCLC Pipeline Report

• On July 07, 2026- Boehringer Ingelheim highlighted a phase III study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3.
• On July 06, 2026- Merck Sharp & Dohme LLC conducted a phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate.
• On July 06, 2026- AbbVie announced a phase 2 study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).
• On July 01, 2026- BioNTech SE initiated a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
• DelveInsight’s Extensive Stage Small Cell Lung Cancer pipeline report depicts a robust space with 25+ ESCLC companies working to develop 30+ pipeline therapies for Extensive Stage Small Cell Lung Cancer treatment.
• The leading Extensive Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
• Promising Extensive Stages Small Cell Lung Cancer Pipeline Therapies such as Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others.

Get insights into ESCLC Clinical Trials and leading companies with DelveInsight @ ESCLC Treatment Drugs

The ESCLC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The ESCLC Pipeline Report also highlights the unmet needs with respect to the ESCLC.

ESCLC Overview

Extensive-Stage Small Cell Lung Cancer (ESCLC) is a rapidly progressing form of lung cancer characterized by its aggressive nature and tendency to spread early to distant parts of the body. Unlike non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers and is strongly associated with smoking. In ESCLC, the cancer has spread beyond the hemithorax and regional lymph nodes, often involving the liver, bone marrow, brain, and adrenal glands. Patients with ESCLC often present with nonspecific symptoms that can include a persistent cough, chest pain, shortness of breath, and hemoptysis (coughing up blood). Due to its extensive nature, systemic symptoms such as weight loss, fatigue, and loss of appetite are common. Paraneoplastic syndromes, which are disorders triggered by an immune response to the cancer, can also occur, leading to conditions such as SIADH (syndrome of inappropriate antidiuretic hormone secretion), Cushing’s syndrome, or Lambert-Eaton myasthenic syndrome.

ESCLC Emerging Drugs Profile

• Serplulimab+Chemo: Shanghai Henlius Biotech

Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).

• Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.

Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).

• RYZ101: RayzeBio, Inc.

RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC).

If you’re tracking ongoing ESCLC Clinical trials, this press release is a must-read @ ESCLC Treatment Drugs

The ESCLC Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment.
• ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market

ESCLC Companies

Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.

Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

ESCLC Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new ESCLC Drugs and Developments with DelveInsight’s expert analysis @ ESCLC Market Drivers and Barriers

Scope of the ESCLC Pipeline Report

• Coverage- Global
• ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
• Extensive Stages Small Cell Lung Cancer Pipeline Therapies- Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others
• ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth ESCLC Pipeline Report today! @ ESCLC Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Serplulimab+Chemo: Shanghai Henlius Biotech
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RYZ101: RayzeBio, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
21. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
22. Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
23. Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
24. Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
25. Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
26. Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight